Keywords: synosia, initiates, proof-of-concept, nitisinone, study, rls, switzerland
Synosia initiates proof-of-concept nitisinone study in RLS
Article | 22 December 2008
Switzerland's Synosia Therapeutics has initiated a proof-of-concept trial to evaluate the efficacy and safety of nitisinone (SYN-118), a potent and ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
